147 related articles for article (PubMed ID: 17547692)
1. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors.
Gomes L; Lemos MC; Paiva I; Ribeiro C; Carvalheiro M; Regateiro FJ
Acta Med Port; 2005; 18(5):339-43. PubMed ID: 16611538
[TBL] [Abstract][Full Text] [Related]
3. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR.
McKeown-Eyssen G; Baines C; Cole DE; Riley N; Tyndale RF; Marshall L; Jazmaji V
Int J Epidemiol; 2004 Oct; 33(5):971-8. PubMed ID: 15256524
[TBL] [Abstract][Full Text] [Related]
4. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer.
Granja F; Morari J; Morari EC; Correa LA; Assumpção LV; Ward LS
Cancer Lett; 2004 Jul; 210(2):151-7. PubMed ID: 15183530
[TBL] [Abstract][Full Text] [Related]
5. The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients.
Ouerhani S; Marrakchi R; Bouhaha R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
Bull Cancer; 2008 Feb; 95(2):E1-4. PubMed ID: 18304900
[TBL] [Abstract][Full Text] [Related]
6. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
[TBL] [Abstract][Full Text] [Related]
7. [CYP2D6 and GSTM1 genetic polymorphism and lung cancer susceptibility].
Gao J; Ren C; Zhang Q
Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):185-6. PubMed ID: 10921002
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 and CYP1A1 mutations in the Turkish population.
Aydin M; Hatirnaz O; Erensoy N; Ozbek U
Cell Biochem Funct; 2005; 23(2):133-5. PubMed ID: 15648054
[TBL] [Abstract][Full Text] [Related]
9. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
10. [Association of genetic polymorphisms and haplotypes in hMLH1 and hMSH3 gene with the risk of papillary thyroid carcinoma].
Shi WP; Bian JC; Jiang F; Ni HX; Zhu QX; Tang HW; Shen Q; Wu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):390-5. PubMed ID: 18683134
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of CYP2D6 in patients with cardiovascular disease -- a cohort study.
Teh LK; Zilfalil BA; Marina I; Rosemi BS; Ismail R
J Clin Pharm Ther; 2004 Dec; 29(6):559-64. PubMed ID: 15584944
[TBL] [Abstract][Full Text] [Related]
12. The association of CYP2D6 *10 polymorphism with breast cancer risk and clinico-pathologic characteristics in Chinese women.
Li H; Feng L; Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Li J; Xie Y
Acta Oncol; 2006; 45(5):597-601. PubMed ID: 16864175
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine hydroxylase (CYP2D6) and prostate cancer.
Febbo PG; Kantoff PW; Giovannucci E; Brown M; Chang G; Hennekens CH; Stampfer M
Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1075-8. PubMed ID: 9865424
[TBL] [Abstract][Full Text] [Related]
14. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 CYP2D6.
Wolf CR; Smith G
IARC Sci Publ; 1999; (148):209-29. PubMed ID: 10493260
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2D6 polymorphism and character traits.
Suzuki E; Kitao Y; Ono Y; Iijima Y; Inada T
Psychiatr Genet; 2003 Jun; 13(2):111-3. PubMed ID: 12782969
[TBL] [Abstract][Full Text] [Related]
18. Thyroid cancer susceptibility and THRA1 and BAT-40 repeats polymorphisms.
Baida A; Farrington SM; Galofré P; Marcos R; Velázquez A
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):638-42. PubMed ID: 15767343
[TBL] [Abstract][Full Text] [Related]
19. [Genetic polymorphism and susceptibility to occupational chronic manganism: a case-control study].
Zheng Y; He F; Chan P; Pan Z; Wang Z; Pan J; Zhou X
Zhonghua Yu Fang Yi Xue Za Zhi; 1999 Mar; 33(2):78-80. PubMed ID: 11864457
[TBL] [Abstract][Full Text] [Related]
20. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
